Introduction
At present, only six drugs are indicated for the treatment of neuropathic pain. In 2010, two significant events impacted the neuropathic pain market: the launch of Qutenza (8% capsaicin patch; NeurogesX/Astellas) in the US and EU; and the high-profile failure of ralfinamide (NW-1029; Newron) for the treatment of neuropathic low back pain.
Features and benefits
* Analysis of patient segmentation, epidemiology, current treatment approaches, and clinical unmet needs.
* In depth analysis of historic (2005–09) and future (2010–19) seven major market prescription sales dynamics.
* Discussion of R&D dynamics and pipeline trends in the neuropathic pain market.
* Commercial and clinical assessment of key late-stage pipeline drugs with country-specific sales forecasts to 2019.
* Insight provided by eight international key opinion leaders.
Highlights
The neuropathic pain market is expected to achieve peak sales of .1bn over the forecast period (2010–19) across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK).In addition to existing brands expanding into new regions, Datamonitor forecasts a total of eight pipeline candidates to enter the neuropathic pain market over the forecast period (2010–19) across the seven major markets.The broad label approval of Nucynta ER (extended-release tapentadol; Johnson & Johnson/Grünenthal) will drive market growth, while the launch of novel and topical agents will broaden treatment options.
Your key questions answered
* Who will be the winners and losers in the future neuropathic pain market?
* What are the key unmet needs in the treatment of neuropathic pain?
* What are the most promising drug candidates in development for the potential treatment of neuropathic pain?
* Which neuropathic pain subtypes represent the most lucrative indications in which to seek regulatory approval?
Table of Contents :
Executive Summary
Strategic scoping and focus
Datamonitor insight into the neuropathic pain market
Related reports
OVERVIEW
Catalyst
Summary
1. PATIENT POTENTIAL
Key findings
Definition of neuropathic pain
Neuropathic pain can be defined by location, etiology, and severity
Diagnosis of neuropathic pain
Patient segmentation
Segmentation of neuropathic pain largely depends on the subtype
Segmentation of neuropathic pain differs depending on the symptoms
Epidemiology of neuropathic pain in the seven major markets
Neuropathic low back pain is the most prevalent of the neuropathic pain indications, affecting an estimated 29 million individuals across the seven major markets
Diabetic neuropathic pain affects an estimated 683,000 patients across the seven major markets
HIV-related neuropathic pain affects an estimated 332,000 people in the seven major markets
Post-herpetic neuralgia affects an estimated 307,000 people across the seven major markets
Other neuropathic pain subtypes
Current management of neuropathic pain
Treatments of neuropathic pain can involve pharmacological and non-pharmacological approaches
Consequences of inadequately treated neuropathic pain
Unmet need in neuropathic pain
The primary unmet need is improved efficacy in pain reduction and management
After efficacy, improved side-effect profile is the second most important unmet need
Reduction in pill burden will be increasingly important in the future with the use of combination therapies
Fewer drug-drug interactions will strengthen pipeline agents profile for use as a conjunctive therapy
Reduced time to onset of action is the least important unmet need
For some-more information, Great fully visit:
Topic: forecast period, low back pain, newron, peak sales, pipeline drugs, prescription sales, promising drug, stage pipeline, tapentadol, winners and losers